Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.2M
2M shares
52-week range
$2.96 – $11.96
23% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
15.44%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $6.2K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| R&D | $4.7M | $6.6M | $5.9M | $5.5M | $6.6M | $5.0M | $3.2M | $1.8M |
| Operating income | −$9.0M | −$10.8M | −$11.5M | −$11.5M | −$13.2M | −$10.5M | −$10.8M | −$5.8M |
| EBITDA | −$9.0M | −$10.8M | −$11.3M | −$11.0M | −$12.9M | −$9.8M | −$11.3M | −$6.9M |
| Net income | −$9.8M | −$13.3M | −$11.7M | −$11.2M | −$13.2M | −$10.1M | −$11.5M | −$7.0M |
| Net margin | -158669.6% | — | — | — | — | — | — | — |
| EPS (diluted) | -43.49 | -41.48 | -12.47 | -5.47 | -6.84 | -5.89 | -10.25 | -8.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $100000 | $-3.54 | $-3.54–$-3.54 | 1 |
| 2027 | $200000 | $-3.04 | $-3.04–$-3.04 | 1 |
Forward consensus · source: Financial Modeling Prep
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
www.endrainc.comNo one on the platform currently holds NDRA.
No tracked institution reports a position in NDRA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-11-07 | 1-for-35reverse |
| 2024-08-20 | 1-for-50reverse |
| 2022-12-09 | 1-for-20reverse |
No one on the platform has traded NDRA yet.
| $837 |
| — |
| GCTKGlucoTrack, Inc. | $0.31 | -5.45% | $177046 | — |
| HSCSHeartSciences Inc. | $2.75 | -6.46% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NDRA Assuming a 350 million market cap for the new company, NOBA, the price would be a double from here. Better to own ASPI I think though.
View on StockTwits ↗ASP Isotopes To Merge Noble Africa With A Unit Of ENDRA – A Look At The Key Contours Of The Deal $ASPI $NDRA https://stocktwits.com/news/equity/markets/aspi-ndra-stock-in-focus-merger-/cZ1GVEHR7XO
View on StockTwits ↗$NDRA It's the details. NDRA would only be 3% of the new company. We get noting for the technology and patents. They are just wanting NDRA Nasdaq ticker symbol placement. This all would have to be approved by shareholders and it should. Management has a lot of explaining and selling to do.
View on StockTwits ↗$NDRA this is great news and down on light volume. Good level to buy
View on StockTwits ↗$NDRA announced a proposed merger of its subsidiary with Noble Africa LLC, a unit of ASP Isotopes.
View on StockTwits ↗$NDRA who on gods earth is genuinely bullish on this!
View on StockTwits ↗$NDRA Any chance anyone is that dumb to buy that company?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.